(Q33588535)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

review article

1 reference

title

Managing resistance to anti-HIV drugs: an important consideration for effective disease management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

Kristel Van Laethem

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

E De Clercq

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

337-361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-199957030-00006

4 December 2019

exact match

0 references

cites work

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

1 reference

12 December 2020

Activity of tethered human immunodeficiency virus 1 protease containing mutations in the flap region of one subunit

1 reference

12 December 2020

Anti-human immunodeficiency virus drug combination strategies

1 reference

12 December 2020

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

1 reference

12 December 2020

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

1 reference

12 December 2020

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

1 reference

12 December 2020

Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients

1 reference

12 December 2020

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

12 December 2020

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

12 December 2020

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

1 reference

12 December 2020

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease

1 reference

12 December 2020

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection

1 reference

12 December 2020

Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates

1 reference

12 December 2020

HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine

1 reference

12 December 2020

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

1 reference

12 December 2020

HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients

1 reference

12 December 2020

Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

1 reference

12 December 2020

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

1 reference

12 December 2020

Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.

1 reference

12 December 2020

Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.

1 reference

12 December 2020

The fidelity of 3' misinsertion and mispair extension during DNA synthesis exhibited by two drug-resistant mutants of the reverse transcriptase of human immunodeficiency virus type 1 with Leu74-->Val and Glu89-->Gly

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

1 reference

12 December 2020

High resolution structures of HIV-1 RT from four RT-inhibitor complexes

1 reference

12 December 2020

Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus

1 reference

12 December 2020

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

12 December 2020

The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.

1 reference

12 December 2020

Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial

1 reference

12 December 2020

Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996

1 reference

12 December 2020

Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates

1 reference

12 December 2020

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects

1 reference

12 December 2020

HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team

1 reference

12 December 2020

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition

1 reference

12 December 2020

Management of drug interactions in patients with HIV.

1 reference

12 December 2020

Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

1 reference

12 December 2020

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

12 December 2020

Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited

1 reference

12 December 2020

Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method

1 reference

12 December 2020

Characterization of HIV-1 strains isolated from patients treated with TIBO R82913.

1 reference

12 December 2020

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

1 reference

12 December 2020

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine

1 reference

12 December 2020

An extensively modified version of MolScript that includes greatly enhanced coloring capabilities

1 reference

12 December 2020

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

12 December 2020

Long-term persistence of AZT-resistance mutations in the plasma HIV-1 of patients removed from AZT therapy

1 reference

12 December 2020

The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity

1 reference

12 December 2020

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

12 December 2020

Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates

1 reference

12 December 2020

The development of resistance of HIV-1 to zalcitabine

1 reference

12 December 2020

Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors

1 reference

12 December 2020

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance

1 reference

12 December 2020

Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus

1 reference

12 December 2020

Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains

1 reference

12 December 2020

HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy

1 reference

12 December 2020

Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo

1 reference

12 December 2020

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo

1 reference

12 December 2020

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

1 reference

12 December 2020

The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro

1 reference

12 December 2020

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

1 reference

12 December 2020

Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group

1 reference

12 December 2020

HIV viral load markers in clinical practice

1 reference

12 December 2020

Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity

1 reference

12 December 2020

Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy

1 reference

12 December 2020

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance

1 reference

12 December 2020

Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

1 reference

12 December 2020

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

1 reference

12 December 2020

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

12 December 2020

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

12 December 2020

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

1 reference

12 December 2020

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

12 December 2020

Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase

1 reference

12 December 2020

Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years

1 reference

12 December 2020

Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS

1 reference

12 December 2020

Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs

1 reference

12 December 2020

Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants

1 reference

12 December 2020

Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase.

1 reference

12 December 2020

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.

1 reference

12 December 2020

Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites

1 reference

12 December 2020

The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA

1 reference

12 December 2020

Viral dynamics of HIV: implications for drug development and therapeutic strategies

1 reference

12 December 2020

Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy

1 reference

12 December 2020

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors

1 reference

12 December 2020

Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis.

1 reference

12 December 2020

The HIV-1 protease as a therapeutic target for AIDS

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

1 reference

12 December 2020

A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine

1 reference

12 December 2020

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study

1 reference

12 December 2020

Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene

1 reference

12 December 2020

Breaking the mother-to-child transmission of HIV-1

1 reference

12 December 2020

HIV-1 sensitivity to zidovudine and clinical outcome in children

1 reference

12 December 2020

Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro

1 reference

12 December 2020

Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients.

1 reference

12 December 2020

Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

2',3'-Dideoxycytidine induced drug resistance in human cells.

1 reference

12 December 2020

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

12 December 2020

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy

1 reference

12 December 2020

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

12 December 2020

Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.

1 reference

12 December 2020

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries

1 reference

12 December 2020

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

1 reference

12 December 2020

Zidovudine induces the expression of cellular resistance affecting its antiviral activity.

1 reference

12 December 2020

Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

12 December 2020

AIDS pathogenesis: from models to viral dynamics in patients

1 reference

12 December 2020

Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

1 reference

12 December 2020

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

12 December 2020

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

1 reference

12 December 2020

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

12 December 2020

Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors

1 reference

12 December 2020

Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy

1 reference

12 December 2020

An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine

1 reference

12 December 2020

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

12 December 2020

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

12 December 2020

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

12 December 2020

Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates

1 reference

12 December 2020

Human immunodeficiency virus type-1 reverse transcriptase. Contribution of Met-184 to binding of nucleoside 5'-triphosphate

1 reference

12 December 2020

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

1 reference

12 December 2020

(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants [...]

1 reference

12 December 2020

Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations

1 reference

12 December 2020

1 reference

12 December 2020

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

1 reference

12 December 2020

Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.

1 reference

12 December 2020

HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee

1 reference

12 December 2020

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

1 reference

12 December 2020

1 reference

12 December 2020

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

12 December 2020

Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections

1 reference

12 December 2020

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

12 December 2020

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

12 December 2020

Clinical experience with non-nucleoside reverse transcriptase inhibitors.

1 reference

12 December 2020

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

12 December 2020

Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes

1 reference

12 December 2020

Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.

1 reference

12 December 2020

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs

1 reference

12 December 2020

Human immunodeficiency virus (HIV) RNA in plasma as the preferred target for therapy in patients with HIV infection: a critique

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine

1 reference

12 December 2020

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

1 reference

12 December 2020

Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs.

1 reference

12 December 2020

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

1 reference

12 December 2020

Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates

1 reference

12 December 2020

Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

1 reference

12 December 2020

Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

1 reference

12 December 2020

Evaluating the cost of medications for ambulatory HIV-infected persons in association with landmark changes in antiretroviral therapy

1 reference

12 December 2020

1 reference

12 December 2020

Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.

1 reference

12 December 2020

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

1 reference

12 December 2020

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

12 December 2020

HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine

1 reference

12 December 2020

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

12 December 2020

A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Identification, purification, and cell culture assays of retroviral proteases

1 reference

12 December 2020

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

1 reference

12 December 2020

Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication

1 reference

12 December 2020

Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.

1 reference

12 December 2020

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

1 reference

12 December 2020

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

12 December 2020

Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

1 reference

12 December 2020

10.2165/00003495-199957030-00006

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193687%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 December 2019

0 references

1 reference